Lipid Disorders Clinic, Department of Internal Medicine, University Hospital of Ioannina, Ioannina, Greece.
JAMA. 2012 Sep 12;308(10):1024-33. doi: 10.1001/2012.jama.11374.
Considerable controversy exists regarding the association of omega-3 polyunsaturated fatty acids (PUFAs) and major cardiovascular end points.
To assess the role of omega-3 supplementation on major cardiovascular outcomes.
MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials through August 2012.
Randomized clinical trials evaluating the effect of omega-3 on all-cause mortality, cardiac death, sudden death, myocardial infarction, and stroke.
Descriptive and quantitative information was extracted; absolute and relative risk (RR) estimates were synthesized under a random-effects model. Heterogeneity was assessed using the Q statistic and I2. Subgroup analyses were performed for the presence of blinding, the prevention settings, and patients with implantable cardioverter-defibrillators, and meta-regression analyses were performed for the omega-3 dose. A statistical significance threshold of .0063 was assumed after adjustment for multiple comparisons.
Of the 3635 citations retrieved, 20 studies of 68,680 patients were included, reporting 7044 deaths, 3993 cardiac deaths, 1150 sudden deaths, 1837 myocardial infarctions, and 1490 strokes. No statistically significant association was observed with all-cause mortality (RR, 0.96; 95% CI, 0.91 to 1.02; risk reduction [RD] -0.004, 95% CI, -0.01 to 0.02), cardiac death (RR, 0.91; 95% CI, 0.85 to 0.98; RD, -0.01; 95% CI, -0.02 to 0.00), sudden death (RR, 0.87; 95% CI, 0.75 to 1.01; RD, -0.003; 95% CI, -0.012 to 0.006), myocardial infarction (RR, 0.89; 95% CI, 0.76 to 1.04; RD, -0.002; 95% CI, -0.007 to 0.002), and stroke (RR, 1.05; 95% CI, 0.93 to 1.18; RD, 0.001; 95% CI, -0.002 to 0.004) when all supplement studies were considered.
Overall, omega-3 PUFA supplementation was not associated with a lower risk of all-cause mortality, cardiac death, sudden death, myocardial infarction, or stroke based on relative and absolute measures of association.
关于欧米伽-3 多不饱和脂肪酸(PUFAs)与主要心血管终点之间的关联,存在相当大的争议。
评估欧米伽-3 补充剂对主要心血管结局的作用。
通过 2012 年 8 月的 MEDLINE、EMBASE 和 Cochrane 对照试验中心注册库进行检索。
评估欧米伽-3 对全因死亡率、心脏死亡、猝死、心肌梗死和中风影响的随机临床试验。
提取描述性和定量信息;采用随机效应模型综合绝对和相对风险(RR)估计值。使用 Q 统计量和 I2 评估异质性。进行了存在盲法、预防设置以及植入式心脏复律除颤器患者的亚组分析,并进行了欧米伽-3 剂量的荟萃回归分析。在进行多次比较调整后,假设统计学意义阈值为.0063。
在检索到的 3635 条引文,纳入了 20 项涉及 68680 名患者的研究,报告了 7044 例死亡、3993 例心脏死亡、1150 例猝死、1837 例心肌梗死和 1490 例中风。全因死亡率(RR,0.96;95%CI,0.91 至 1.02;风险降低[RD] -0.004,95%CI,-0.01 至 0.02)、心脏死亡(RR,0.91;95%CI,0.85 至 0.98;RD,-0.01;95%CI,-0.02 至 0.00)、猝死(RR,0.87;95%CI,0.75 至 1.01;RD,-0.003;95%CI,-0.012 至 0.006)、心肌梗死(RR,0.89;95%CI,0.76 至 1.04;RD,-0.002;95%CI,-0.007 至 0.002)和中风(RR,1.05;95%CI,0.93 至 1.18;RD,0.001;95%CI,-0.002 至 0.004)的相对和绝对关联措施均无统计学意义。
总体而言,基于相对和绝对关联措施,欧米伽-3 多不饱和脂肪酸补充剂与全因死亡率、心脏死亡、猝死、心肌梗死或中风的风险降低无关。